Influence of Pulmonary Surfactant on in Vitro Bactericidal Activities of Amoxicillin, Ceftazidime, and Tobramycin

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1995 Feb 1

PMID 7726491

Citations 16

Authors

A van t Veen

J W Mouton

D Gommers

J A Kluytmans

P Dekkers

B Lachmann

Affiliations

Soon will be listed here.

Abstract

The influence of a natural pulmonary surfactant on antibiotic activity was investigated to assess the possible use of exogenous surfactant as a vehicle for antibiotic delivery to the lung. The influence of surfactant on the bactericidal activity of amoxicillin was tested against Staphylococcus aureus and Streptococcus pneumoniae, and the influence of surfactant on the activities of ceftazidime and tobramycin was tested against Klebsiella pneumoniae, Pseudomonas aeruginosa, S. aureus, and S. pneumoniae. In vitro antibiotic activity was determined by killing curve studies in media with and without surfactant. Amoxicillin and ceftazidime activities were not changed in the presence of surfactant, except for a decreased killing rate of S. pneumoniae by ceftazidime in medium with additional rabbit serum. In contrast, killing curves with low concentrations of tobramycin (0.25x and 1x the MIC) showed a decreased level of activity of tobramycin against all pathogens tested in the presence of surfactant. With higher tobramycin concentrations (4x the MIC) killing rates were decreased less or were unchanged in the presence of surfactant. Concluding from the results of the study, both amoxicillin and ceftazidime can be combined with surfactant without the loss of activity. For mixing surfactant with tobramycin, dosages should be adjusted to overcome the partial inactivation of tobramycin by surfactant.

Citing Articles

Structural and Functional Mimicry of the Antimicrobial Defensin Plectasin by Analogues with Engineered Backbone Composition.

Harmon T, Song J, Gulewicz A, Di Y, Horne W, Seth Horne W Chembiochem. 2024; 26(5):e202400951.

PMID: 39714882 PMC: 11875557. DOI: 10.1002/cbic.202400951.

Barriers that Inhaled Particles Encounter.

Patel B, Gupta N, Ahsan F J Aerosol Med Pulm Drug Deliv. 2024; 37(5):299-306.

PMID: 39388690 PMC: 11520697. DOI: 10.1089/jamp.2024.27498.bp.

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant .

Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N Antibiotics (Basel). 2022; 11(9).

PMID: 36139979 PMC: 9494975. DOI: 10.3390/antibiotics11091201.

Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro.

Nussbaumer-Proll A, Zeitlinger M Pharmaceutics. 2020; 12(8).

PMID: 32823957 PMC: 7464672. DOI: 10.3390/pharmaceutics12080773.

Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic Hollow-Fiber Infection Model.

Heffernan A, Sime F, Sarovich D, Neely M, Guerra-Valero Y, Naicker S Antimicrob Agents Chemother. 2020; 64(9).

PMID: 32660986 PMC: 7449155. DOI: 10.1128/AAC.00879-20.

References

Kharasch V, Sweeney T, Fredberg J, Lehr J, Damokosh A, Avery M . Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis. 1991; 144(4):909-13. DOI: 10.1164/ajrccm/144.4.909. View

Goldstein F, Acar J . Testing Staphylococcus aureus for resistance to beta-lactams. J Antimicrob Chemother. 1991; 27(4):549-50. DOI: 10.1093/jac/27.4.549. View

Eijking E, van Daal G, Tenbrinck R, Luijendijk A, Sluiters J, Hannappel E . Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med. 1991; 17(8):475-8. DOI: 10.1007/BF01690770. View

Barry A, Reller L, Miller G, Washington J, Schoenknect F, Peterson L . Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides. J Clin Microbiol. 1992; 30(3):585-9. PMC: 265114. DOI: 10.1128/jcm.30.3.585-589.1992. View

van Daal G, BOS J, Eijking E, Gommers D, Hannappel E, Lachmann B . Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis. 1992; 145(4 Pt 1):859-63. DOI: 10.1164/ajrccm/145.4_Pt_1.859. View

Unertl K, Lenhart F, Forst H, Peter K . Systemic antibiotic treatment of nosocomial pneumonia. Intensive Care Med. 1992; 18 Suppl 1:S28-34. DOI: 10.1007/BF01752974. View

Bressolle F, de La Coussaye J, Ayoub R, Fabre D, Gomeni R, Saissi G . Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother. 1992; 36(7):1404-11. PMC: 191594. DOI: 10.1128/AAC.36.7.1404. View

Baldwin D, Honeybourne D, Wise R . Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother. 1992; 36(6):1176-80. PMC: 190300. DOI: 10.1128/AAC.36.6.1176. View

Gommers D, Vilstrup C, BOS J, Larsson A, Werner O, Hannappel E . Exogenous surfactant therapy increases static lung compliance, and cannot be assessed by measurements of dynamic compliance alone. Crit Care Med. 1993; 21(4):567-74. DOI: 10.1097/00003246-199304000-00019. View

10.

Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin M . Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis. 1993; 147(5):1279-82. DOI: 10.1164/ajrccm/147.5.1279. View

11.

Ramsey B, Dorkin H, Eisenberg J, Gibson R, HARWOOD I, Kravitz R . Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993; 328(24):1740-6. DOI: 10.1056/NEJM199306173282403. View

12.

RUBENIS M, KOZIJ V, JACKSON G . LABORATORY STUDIES ON GENTAMICIN. Antimicrob Agents Chemother (Bethesda). 1963; 161:153-6. View

13.

POTTER J, MATTHEWS L, Spector S, LEMM J . Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics. 1965; 36(5):714-20. View

14.

SAGGERS B, Lawson D . In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Child. 1968; 43(230):404-9. PMC: 2019980. DOI: 10.1136/adc.43.230.404. View

15.

Jalowayski A, Giammona S . The interaction of bacteria with pulmonary surfactant. Am Rev Respir Dis. 1972; 105(2):236-41. DOI: 10.1164/arrd.1972.105.2.236. View

16.

Zimelis V, JACKSON G . Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis. 1973; 127(6):663-9. DOI: 10.1093/infdis/127.6.663. View

17.

Young L, HEWITT W . Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother. 1973; 4(6):617-25. PMC: 444607. DOI: 10.1128/AAC.4.6.617. View

18.

Bryant R, Hammond D . Interaction of purulent material with antibiotics used to treat Pseudomonas infections. Antimicrob Agents Chemother. 1974; 6(6):702-7. PMC: 444723. DOI: 10.1128/AAC.6.6.702. View

19.

Brain J, Knudson D, Sorokin S, Davis M . Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976; 11(1):13-33. DOI: 10.1016/0013-9351(76)90107-9. View

20.

Washington 2nd J, Snyder R, Kohner P, Wiltse C, Ilstrup D, McCALL J . Effect of cation content of agar on the activity of gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. J Infect Dis. 1978; 137(2):103-11. DOI: 10.1093/infdis/137.2.103. View